Fierce Pharma7d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Optinose to be acquired by Boston-based Paratek Pharmaceuticals in potential $330M deal
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Stocktwits on MSN7d
Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight
Shares of Optinose, Inc. (OPTN) rocketed about 55% on Thursday after privately held Paratek Pharmaceuticals announced that it ...
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will ...
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
The National Law Review9d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire ...